Stifel Maintains Buy Rating on Mirum Pharmaceuticals, Sets $156 Target
Stifel maintained its Buy rating on Mirum Pharmaceuticals and a $156 price target. The target implies 95.1% upside from the October 14 close of $79.96.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.